{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:20:43Z","timestamp":1788412843318,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Swedish Heart and Lung Foundation","doi-asserted-by":"publisher","award":["20220680"],"award-info":[{"award-number":["20220680"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aims to assess pharmacological treatment patterns and outcomes according to the coexistence of heart failure (HF) and Type 2 diabetes (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Two cohorts were derived: HF patients with\/without T2DM and T2DM patients with\/without HF, by linking the Swedish HF Registry, the National Diabetes Registry, and other national registries in 2017\u20132021. In 37 903 patients with HF (35% females, median age 74), T2DM was independently associated with a 10-fold higher use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) and less likely use of mineralocorticoid receptor antagonists (MRAs) irrespective of ejection fraction (EF), and of renin\u2013angiotensin inhibitors (RASis)\/angiotensin receptor\u2013neprilysin inhibitors (ARNis) in HF with reduced and mildly reduced EF. Over a median follow-up of 1.8\u2005years, T2DM was independently associated with higher risk of first HF hospitalization (HHF)\/cardiovascular (CV) death, first HHF, and all-cause death, but not with CV death alone. In 16 266 patients with T2DM (29% females, median age 76), HF was independently associated with more likely use of SGLT2i but less likely use of metformin. Over a median follow-up of 2.2\u2005years, HF was independently associated with higher risk of CV death, all-cause death, and myocardial infarction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HF, T2DM was associated with higher use of SGLT2i and lower use of MRA and RASi\/ARNI despite being linked with a higher risk of death and HHF. In T2DM, presence of HF was linked with higher SGLT2i use and an independent higher risk of death and myocardial infarction. Heart failure was associated with comparatively greater risk increase than T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf504","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:47:34Z","timestamp":1755085654000},"page":"64-77","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and Type 2 diabetes: data from the Swedish Heart Failure Registry and National Diabetes Registry"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2116-3293","authenticated-orcid":false,"given":"Francesca","family":"Musella","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Sjukhusbacken 10 Stockholm 118 83 ,","place":["Sweden"]},{"name":"Cardiology Department, Santa Maria Delle Grazie Hospital , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-7435","authenticated-orcid":false,"given":"Giulia","family":"Ferrannini","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Sjukhusbacken 10 Stockholm 118 83 ,","place":["Sweden"]},{"name":"Internal Medicine Unit, S\u00f6dert\u00e4lje Hospital , S\u00f6dert\u00e4lje ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soffia","family":"Gudbj\u00f6rnsdottir","sequence":"additional","affiliation":[{"name":"National Diabetes Registry, Centre of Registries , Gothenburg ,","place":["Sweden"]},{"name":"Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Guidetti","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Sjukhusbacken 10 Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Boccalatte","sequence":"additional","affiliation":[{"name":"Cardiology Department, Santa Maria Delle Grazie Hospital , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerolamo","family":"Sibilio","sequence":"additional","affiliation":[{"name":"Cardiology Department, Santa Maria Delle Grazie Hospital , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Orsini","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin Corovic","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Sjukhusbacken 10 Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4781-9588","authenticated-orcid":false,"given":"Raffaele","family":"Scorza","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Sjukhusbacken 10 Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institute , Sjukhusbacken 10 Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2026010607171508200_zwaf504-B1","doi-asserted-by":"crossref","first-page":"1192629","DOI":"10.3389\/fendo.2023.1192629","article-title":"The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the global burden of disease study 2019","volume":"14","author":"Ye","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026010607171508200_zwaf504-B2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"2026010607171508200_zwaf504-B3","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026010607171508200_zwaf504-B4","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"2026010607171508200_zwaf504-B5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010607171508200_zwaf504-B6","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010607171508200_zwaf504-B7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010607171508200_zwaf504-B8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ejhf.3112","article-title":"The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry","volume":"26","author":"Tomasoni","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010607171508200_zwaf504-B9","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s11606-007-0313-2","article-title":"Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients\u2019 treatment priorities and self-management?","volume":"22","author":"Kerr","year":"2007","journal-title":"J Gen Intern Med"},{"key":"2026010607171508200_zwaf504-B10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"2026010607171508200_zwaf504-B11"},{"key":"2026010607171508200_zwaf504-B12"},{"key":"2026010607171508200_zwaf504-B13","doi-asserted-by":"crossref","first-page":"e026708","DOI":"10.1161\/JAHA.122.026708","article-title":"Persistent high burden of heart failure across the ejection fraction spectrum in a nationwide setting","volume":"11","author":"Stolfo","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026010607171508200_zwaf504-B14","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.120.045810","article-title":"Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study","volume":"142","author":"Sanders-van Wijk","year":"2020","journal-title":"Circulation"},{"key":"2026010607171508200_zwaf504-B15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2020.04.068","article-title":"Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: a blueprint for clinical trial design","volume":"313","author":"Savarese","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026010607171508200_zwaf504-B16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026010607171508200_zwaf504-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.006540","article-title":"Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease","volume":"6","author":"Cooper","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026010607171508200_zwaf504-B18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/bmj.327.7418.812","article-title":"Diabetes may be independent risk factor for hyperkalaemia","volume":"327","author":"Jarman","year":"2003","journal-title":"BMJ"},{"key":"2026010607171508200_zwaf504-B19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010607171508200_zwaf504-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010607171508200_zwaf504-B21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ejhf.3214","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC council for cardiology practice","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010607171508200_zwaf504-B22","doi-asserted-by":"crossref","first-page":"1385281","DOI":"10.3389\/fcvm.2024.1385281","article-title":"The management of heart failure in Sweden-the physician\u2019s perspective: a survey","volume":"11","author":"Ferrannini","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026010607171508200_zwaf504-B23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026010607171508200_zwaf504-B24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010607171508200_zwaf504-B25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/eurjpc\/zwad223","article-title":"Prevalence of heart failure stages in the general population and implications for heart failure prevention: reports from the China hypertension survey 2012\u201315","volume":"30","author":"Cai","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026010607171508200_zwaf504-B26","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/eurjpc\/zwae121","article-title":"Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction","volume":"31","author":"Schupp","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026010607171508200_zwaf504-B27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"2026010607171508200_zwaf504-B28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2026010607171508200_zwaf504-B29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/eurjpc\/zwad322","article-title":"Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study","volume":"31","author":"Jang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026010607171508200_zwaf504-B30","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ejhf.2971","article-title":"Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry","volume":"25","author":"Stolfo","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf504\/64039570\/zwaf504.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/1\/64\/64039570\/zwaf504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/1\/64\/64039570\/zwaf504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:17:27Z","timestamp":1767701847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/1\/64\/8234012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf504","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,8,14]]}}}